COLOTAN is a brand that focuses on advancing doctoral training and research in innovative colon targeting drugs. Their goal is to obtain a high concentration of drugs in the colon in order to effectively treat diseases of the large intestine. They address the challenges related to pharmacokinetics and bioavailability that often lead to the attrition of oral drug candidates.

The brand acknowledges the importance of oral administration due to its non-invasive nature and convenience for patients. They emphasize the need for new predictive tools, innovative drug delivery systems, and precision medicine approaches in order to improve drug performance in the colon. COLOTAN offers oral formulations that release drugs in a pH- or time-dependent manner in the colon.

These formulations are used for topical treatment of colonic diseases such as inflammatory bowel diseases (IBD) and controlled release of drugs for systemic treatment. The brand also conducts research, publishes articles, and organizes symposiums to share knowledge and advancements in the field. COLOTAN is funded by the European Union's Horizon 2020 research and innovation program